agilon health inc header image

agilon health inc

AGL

Equity

ISIN US00857U1079 / Valor 110653729

New York Stock Exchange, Inc (2024-11-19)
USD 1.59+1.27%

agilon health inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Agilon Health Inc. operates as a healthcare company that focuses on transforming the primary care model for senior patients through its Medicare-centric Total Care Model. This innovative approach leverages a unified operating platform that integrates people, processes, and technology to assist physician partners in identifying care gaps, enhancing practice growth, and improving patient outcomes. Unlike companies that aim to own or directly manage physician practices, Agilon positions itself as a collaborative partner, investing 100% of the capital in joint ventures with independent primary-care and multispecialty practices. These partnerships are designed to maintain the autonomy of physicians while enabling them to manage global risk more effectively. Agilon's model emphasizes the importance of the physician-patient relationship and supports the long-term financial sustainability of practices. The company has established strategic relationships with leading national and regional health plans, facilitating a focus on delivering consistent, high-quality care and managing overall health costs efficiently. Through its approach, Agilon aims to empower physicians to deliver superior care to their communities while navigating the complexities of the healthcare system.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (07.08.2024):

Revenue Growth

agilon health inc. reported a significant increase in total revenue for the first quarter of 2024, reaching $1.60 billion. This represents a 52% growth compared to the $1.05 billion reported in the first quarter of 2023. The substantial revenue growth highlights the company's expanding footprint and successful execution of its business strategies.

Membership Expansion

As of March 31, 2024, agilon health inc. saw a notable increase in its membership base. The total number of members on the agilon platform grew to 654,000, which includes 523,000 Medicare Advantage members and 131,000 ACO model beneficiaries. This marks a 43% increase in Medicare Advantage membership compared to the same period last year.

Gross Profit

In the first quarter of 2024, agilon health inc. reported a gross profit of $75 million, slightly up from $73 million in the first quarter of 2023. Despite the modest increase, the company continues to focus on enhancing its profitability through various strategic initiatives and operational efficiencies.

Net Loss

agilon health inc. experienced a net loss of $6 million in the first quarter of 2024, a significant shift from the net income of $16 million reported in the first quarter of 2023. The net loss was influenced by various factors, including prior year claims and adjustments in the current funding environment for Medicare Advantage.

Adjusted EBITDA

For the first quarter of 2024, agilon health inc. reported an Adjusted EBITDA of $29 million, reflecting a 21% increase from the $24 million reported in the first quarter of 2023. The improvement in Adjusted EBITDA underscores the company's ongoing efforts to drive operational efficiency and profitability.

Summarized from source with an LLMView Source

Key figures

-86.7%1Y
-93.3%3Y
%5Y

Performance

85.2%1Y
69.1%3Y
66.5%5Y

Volatility

Market cap

2657 M

Market cap (USD)

Daily traded volume (Shares)

768,275

Daily traded volume (Shares)

1 day high/low

1.62 / 1.525

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Roche Holding Ltd
Roche Holding Ltd Roche Holding Ltd Valor: 1203211
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.97%CHF 266.20
Sonova Holding Ltd.
Sonova Holding Ltd. Sonova Holding Ltd. Valor: 1254978
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-5.21%CHF 300.40
Tecan Group Ltd.
Tecan Group Ltd. Tecan Group Ltd. Valor: 1210019
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.29%CHF 208.20
Ipsen
Ipsen Ipsen Valor: 2348805
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.66%EUR 107.20
Terveystalo Oyj
Terveystalo Oyj Terveystalo Oyj Valor: 37893402
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.71%EUR 9.75
Beiersdorf AG
Beiersdorf AG Beiersdorf AG Valor: 324660
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.26%EUR 121.40
Draegerwerk AG & Co. KGaA
Draegerwerk AG & Co. KGaA Draegerwerk AG & Co. KGaA Valor: 330446
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.26%EUR 42.95
GeneDx Holdings Corp
GeneDx Holdings Corp GeneDx Holdings Corp Valor: 126808031
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.08%USD 71.04
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC Hikma Pharmaceuticals PLC Valor: 2324471
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.04%GBP 18.38
Getinge AB
Getinge AB Getinge AB Valor: 84926
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.90%SEK 171.10